Novartis Persists In Challenge To Indian Patent Law; India Rejects More AIDS Drugs Patents
Undeterred by two previous decisions by Indian authorities holding that under Indian Patent Law, its leukaemia drug - Gleevec is not patentable, Novartis now wants to take the fight to the Indian Supreme Court. Meanwhile, also this week, sources say Indian authorities rejected applications for patents on two HIV/AIDS drugs, opening the way for cheaper generic versions to be developed and marketed.
